CCC
MRNA icon

Chelsea Counsel Company’s Moderna MRNA Stock Holding History

Chelsea Counsel Company’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7K Hold
100
– – ﹤0.01% 177
2026
Q1 		$5.08K Hold
100
– – ﹤0.01% 187
2025
Q4 		$2.95K Sell
100
-2
-2% -$54 ﹤0.01% 199
2025
Q3 		$2.63K Hold
102
– – ﹤0.01% 201
2025
Q2 		$2.81K Hold
102
– – ﹤0.01% 193
2025
Q1 		$2.89K Sell
102
-6,757
-99% -$240K ﹤0.01% 190
2024
Q4 		$285K Sell
6,859
-545
-7% -$26K 0.15% 85
2024
Q3 		$495K Sell
7,404
-635
-8% -$58.3K 0.24% 68
2024
Q2 		$955K Buy
8,039
+4,005
+99% +$507K 0.48% 43
2024
Q1 		$430K Sell
4,034
-198
-5% -$20K 0.24% 62
2023
Q4 		$421K Sell
4,232
-1,550
-27% -$130K 0.22% 72
2023
Q3 		$597K Sell
5,782
-70
-1% -$7.81K 0.31% 63
2023
Q2 		$711K Buy
5,852
+70
+1% +$9.34K 0.35% 58
2023
Q1 		$888K Hold
5,782
– – 0.43% 51
2022
Q4 		$1.04M Sell
5,782
-420
-7% -$68.7K 0.52% 47
2022
Q3 		$733K Sell
6,202
-50
-0.8% -$7.59K 0.45% 54
2022
Q2 		$893K Sell
6,252
-128
-2% -$18.3K 0.46% 52
2022
Q1 		$1.1M Sell
6,380
-25
-0.4% -$4.21K 0.48% 47
2021
Q4 		$1.63M Buy
+6,405
New +$1.87M 0.7% 35

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Chelsea Counsel Company's MRNA Position: Q2 2026 in Review

Chelsea Counsel Company held its Moderna (MRNA) position steady in Q2 2026 at 100 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #177.

Chelsea Counsel Company first reported a position in MRNA in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.63M in Q4 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Chelsea Counsel Company held 100 shares of Moderna worth $7K as of Q2 2026.
  • Chelsea Counsel Company left its Moderna share count unchanged in Q2 2026.
  • Moderna made up ﹤0.01% of Chelsea Counsel Company's portfolio in Q2 2026, its #177 holding.
  • Chelsea Counsel Company first reported a position in Moderna in Q4 2021 and has held it in 19 quarters since.
  • Chelsea Counsel Company's Moderna position peaked at $1.63M in Q4 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Chelsea Counsel Company's 13F filing for Q2 2026, filed 12 Aug 2026.